Correction to: Oncogene https://doi.org/10.1038/onc.2014.138; published online 2 June 2014.
Since the online publication of the above article, the authors have noted errors in subfigures 1c and 3b. Therefore, new images of the original immmunocytochemistry stainings have been obtained for Fig. 1c, and the Western blots for siRNA-mediated FYN knockdown in Fig. 3b were repeated. The amended versions of Figs. 1c and 3b are now shown below. The conclusions of this paper are not affected, and the authors sincerely apologize for these errors.
.
.
Change history
11 November 2019
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Elias, D., Vever, H., Lænkholm, AV. et al. Correction: Gene expression profiling identifies FYN as an important molecule in tamoxifen resistance and a predictor of early recurrence in patients treated with endocrine therapy. Oncogene 37, 5585–5586 (2018). https://doi.org/10.1038/s41388-018-0495-6
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41388-018-0495-6
